

The Trustees present their annual report and the financial statements of the Charity for the year ending 31 March 2025.

The financial statements comply with current statutory requirements, the Charity's governing document, and the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland

Structure, Governance And Management

Fight Bladder Cancer became registered as an unincorporated charity on 8 July 2014.

The unincorporated charity (1157763) is governed by its present constitution, which was adopted on 14 July 2013 and amended on 29 June 2014.

Fight Bladder Cancer was registered as a Charitable Incorporated Organisation on 28 April 2022 (1198773) and recognised as a cross-border charity in Scotland on 27 July 2022 (SC051881). The Charitable Incorporated Organisation is governed by its present constitution, which was registered on 28 April 2022.

The Charity Commission of England and Wales approved merging the unincorporated charity with the Charitable Incorporated Organisation on 19 April 2023.

Our History

Fight Bladder Cancer was founded by Andrew Winterbottom and his wife Tracy Staskevich in 2010 after Andrew's initial diagnosis and subsequent Stage 4 bladder cancer diagnosis. They discovered a lack of available support for bladder cancer patients and their families in the UK and set out to provide that support through an online support forum and website. The charity officially became registered as an unincorporated charity in 2014 and has since focused on raising awareness for bladder cancer. In 2017, a new Board of Trustees was formed. In 2019, upon receiving a terminal bowel cancer diagnosis, Andrew stepped down, and recruited Dr Lydia Makaroff as the Chief Executive. Lydia managed and led the team with guidance from the Board of

Trustees. Lydia stepped down as CEO in December 2024 when Melanie Costin took over as Interim CEO until May 2025.

Sadly, both Andrew and John Hester, who both served as Chair of Fight Bladder Cancer, passed away in 2019 and 2023, respectively. Deborah Major stepped up as Interim Chair of Fight Bladder Cancer after John Hester's death in February 2023. Andrew Dearden was elected as the Chair of the Trustees in July 2023 and continues to lead the charity in collaboration with the other Trustees.

The Board Of Trustees

The Trustees are responsible for the governance and strategy of the Charity. The constitution of the Charitable Incorporated Organisation (1198773) requires a minimum of three and a maximum of 13 Trustees at any one time.

During this financial year, all Trustee meetings were held via Zoom.

The Trustees who served during the year and up to the date of signature of the financial statements of this Charitable Incorporated Organisation were:

Alison Jane Birtle	Since 28 April 2022
Valerie Ann Hester	Since 28 April 2022
Dorothy Mary Markham	(resigned April 2025)
Paul Ian Michaels	Since 28 April 2022
Andrew Richard Dearden	Since 28 April 2022
Hilary Mary Baker	Since 31 October 2023
Johnstone Shaw	Since 31 October 2023

The Board of Trustees established a balanced mix of governance, business, healthcare and administration skills. The majority of our Trustees continue to be bladder cancer patients or carers and medical professionals .

Fight Bladder Cancer supports the principles of good governance in the Charity.

Governance Code For Smaller Charities

Trustees have independent control over and legal responsibility for the Charity's management and administration.

They must: comply with the Charity's governing document and the law; act in the Charity's best interests; manage the Charity's resources responsibly; act with reasonable care and skill; and ensure the Charity is accountable.

Trustee recruitment, induction and training

To recruit new Trustees, the Chair (with support from their fellow Trustees and the CEO) identifies the skills and insight required on the board to deliver the Charity's strategy. A volunteer job specification is drafted and approved before being advertised widely. This includes Fight Bladder Cancer's social media outlets, online recruitment sites and a direct approach to individuals with the appropriate skill sets.

Potential applicants are invited to submit a CV and, if shortlisted, will be interviewed by the Chair and another Trustee.

On appointment, the new Trustees attend an induction via an online meeting with the principal staff and identify areas in which they may wish to take a particular interest. New Trustees are provided with an induction pack, including a copy of the constitution, recent Trustee board minutes, accounts, financial reports and helpful publications such as Scottish Charity Regulator's Guidance and good practice for Charity Trustees and the Charity Commission's The Essential Trustee.

Principle Staff

Dr. Lydia Makaroff, CEO (resigned December 2024)

Melanie Costin, Interim CEO (December 2024 - May 2025)

Bankers

Lloyds Bank PLC

27-31 White Hart Street
High Wycombe
Buckinghamshire
HP11 2HL

Solicitors

Brian S. Regler

REGLER & COMPANY
98 High Street, Thame
Oxon OX9 3EH

Independent Examiners

Charles Ssempijja FCA

NfP Accountants Ltd
Chartered Accountants
3rd Floor,
86-90 Paul Street
London EC2A 4NE

Related Parties

Fight Bladder Cancer Trading Ltd was a related party of the Charity. It was wholly owned by the charity as its trading subsidiary. It was registered with Companies House with Company number 09988853. It was a private limited company incorporated on 4

February 2016. It was dissolved on 04 July 2023, because future trading activities will be carried out through the Charitable Incorporated Organisation.

The other related parties are the Trustees and those individuals connected with them, including family members, business associates, and other charities in which they are involved. Trustees' terms of office vary, with some positions having fixed terms and others not. Trustees serve without remuneration for their roles. However, they are entitled to claim reimbursement for reasonable expenses, such as travel costs associated with attending Trustee meetings.

Each Trustee must disclose any potential or actual conflicts of interest to the Chair at Trustee meetings when relevant. In line with Charity Commission guidance, details of positions held by Trustees outside of the Charity are available to the public upon request from the Office Manager.

Remuneration Policy For Key Management Personnel

Fight Bladder Cancer ensures fair and competitive remuneration for our staff, particularly key management personnel such as the CEO to attract and retain the expertise necessary for effectively delivering our vision and mission. The Board of Trustees, responsible for setting these remuneration levels, adopts a comprehensive and multifaceted approach in its decision-making process.

This approach includes benchmarking against pay levels for CEOs in other charities of comparable size and income, alongside evaluating the skills, experience, and unique contributions of each individual. Additionally, the board carefully considers the need to attract and retain skilled individuals who can help achieve our charity's goals, while maintaining fiscal responsibility and upholding our organisational values. This policy is part of our broader strategy to foster an inclusive and equitable work environment.

Charity Objects and Public benefit

The Charity's objects are set out in its constitution, as summarised below:

- the provision of support and assistance to patients diagnosed with bladder cancer, their families, friends, and carers
- the provision of information on the subject of bladder cancer, its symptoms, range, treatments, and aftercare needs

- promoting awareness campaigns regarding the causes, symptoms, treatments and aftercare to the public and within the medical profession
- Supporting research into the nature, causes, diagnosis, prevention, treatment, and cure of bladder cancer
- promoting and advocating for effective policies for the prevention, care, treatment, and support for people affected by bladder cancer

Fight Bladder Cancer is the voice of all those affected by bladder cancer in the UK. The Charity was founded by patients and carers and will keep the patient at the heart of all our work. We are making a difference, but there is still much more to do. We will continue to fight bladder cancer for as long as there is a need.

Our Vision:

A future where everyone survives bladder cancer and lives long and well.

Our Mission:

To lead the fight against bladder cancer driven by patient and family insights

Our Values:

- Patient-led
- Compassionate
- Action-orientated
- Ambitious

Our work delivers public benefit by providing information, advice and support to anyone affected by a bladder cancer diagnosis. Our activities aim to reach diverse audiences, ensuring equity in awareness and support services.

This information and support helps people live better with their bladder cancer by reducing the isolation that can come with a bladder cancer diagnosis, providing clarity on their treatment options and improving their quality of life with strategies to minimise the negative impact of treatment.

Our Bladder Cancer Awareness Month campaign reaches a broader audience, equipping people with awareness of the signs and symptoms of bladder cancer. This

empowers them to speak with their GP Practice if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment.

In addition to this, we are actively expanding our outreach efforts. A growing aspect of our awareness work involves reaching out to other organisations, such as trade unions and professional bodies, by participating in their meetings and conferences. This initiative aims to raise our profile and further disseminate valuable information.

Our website, posters, handouts and information booklets raise awareness of the signs and symptoms of bladder cancer among patients, carers, GPs, consultants, nurse specialists and other healthcare professionals – increasing the likelihood of earlier diagnosis and effective treatment.

Our booklets also provide much needed, accessible information for patients and health professionals on aspects of the bladder cancer journey, thus enhancing the care of bladder cancer patients.

The Trustees affirm their commitment to the guidelines on public benefit set forth by both the Charity Commission and the Office of the Scottish Charity Regulator.

In making decisions and setting strategies, due regard has always been given to the guidance provided by these regulatory bodies to ensure that our activities and objectives consistently deliver public benefit. This commitment is fundamental to our operations and guides our actions as we strive to support individuals and communities affected by bladder cancer.

Achievements and Performance

In 2022, 22,636 people in the UK were diagnosed with bladder cancer — 20,839 in England, 925 in Scotland, 591 in Wales, and 281 in Northern Ireland —while more than 100,000 people in the UK are living with the condition*. These numbers highlight the immense responsibility that Fight Bladder Cancer faces in tackling this critical health issue. If you are affected by bladder cancer, please join our support group.

It is with great pleasure that we present to you the 2024-2025 Trustees Report, which outlines the successes and challenges faced by the charity over the past year. Despite the many obstacles that we have encountered, we have continued to make great strides towards our mission of improving the lives of those affected by bladder cancer.

* Data on bladder cancer diagnoses sourced from NHS Cancer Data (England), Scottish Cancer Registry (Scotland), Wales Cancer Intelligence and Surveillance Unit (Wales), and Northern Ireland Cancer Registry (Northern Ireland). The figures pertain to the most recent available data.

Chairman's statement

This year has been one of change and challenges.

We were sad to say goodbye to our long-standing CEO Lydia, who left for pastures new, appointed as the new CEO of an international charity association. We were led by our wonderful Melanie, our Director of Patient Engagement & Support, who stood in as our interim CEO for 6 months, well supported by all our staff, until we were excited to appoint Alison Stunt, as our permanent CEO. Ali has extensive experience in leading UK charities, both at home and internationally, founding and leading Pancreatic Cancer Action in 2010, coincidentally, the same year that FBC was founded.

Fundraising, as any charity will tell you, is getting more difficult with each passing year, due to the economic environment and personal challenges people face, yet FBC, in 2024-2025, has had more raised for it, and donated to us than in any other previous year.

We are incredibly grateful to all our fantastic fundraisers and grant makers who raised vital funds for us. Of special note is the generosity of the Dianne & Graham Roberts Settlement Trust which gave us £250,000 in memory of Graham Roberts. This amazing donation allowed us to, for example, print a year's worth of our patient information booklets at one go, which we send to anyone who requests them, for free.

In 2022, 22,636 people in the UK were diagnosed with bladder cancer — 20,839 in England, 925 in Scotland, 591 in Wales, and 281 in Northern Ireland — while more than 100,000 people in the UK are living with the condition. These numbers highlight the immense responsibility that Fight Bladder Cancer faces in tackling this critical health issue.

I am happy to report that in 2024-2025 we have had many new people (patients, families and professionals) join our online support forum, request our patient information booklets, view our online information videos, invite us to their conferences, companies and meetings and help us with our aims to support patients and their families and in raising awareness of bladder cancer: one of the most common, yet least known about, cancers in the UK.

The Board and I wish to thank all our incredible staff for their tireless work this year in their continued support of patients and their families, especially amid the changes and challenges we have faced.

In the coming year we intend to take on additional staff to help support FBC with our fundraising, policy work and digital / online presence and patient support. Our driving purpose is for patients with bladder cancer to be diagnosed earlier, receive the very best treatments and support and to live long and well after their diagnosis.

Thank you for all you do and have done, and hopefully will do, to help us support patients.

Dr. Andrew Dearden

A handwritten signature in black ink, appearing to read "A Dearden", with a long horizontal line extending to the right.

Chair of Trustees

We carefully monitor and evaluate our progress to optimise our resources and demonstrate our impact in these four pillars of Fight Bladder Cancer's activities:

Patient Support

Giving information, guidance, peer to peer support and advice to patients and their families in order to enhance patient experience and ultimately to improve quality of life.

Awareness

Raising awareness of the signs and symptoms of bladder cancer to the public and medical professionals in order to improve early diagnosis, patient outcomes and survival for the disease.

Policy and advocacy

Utilising the patient voice to campaign for policy change at both national and regional levels across the UK, including the devolved nations. We aim to improve patient care, eliminate inequalities in time to diagnosis, improve access to treatments for all affected by bladder cancer.

Research

Working with patients to help improve clinical trial design, provide public patient involvement in bladder cancer research activities and to influence research investment and priorities.

Our Patient Support Services:

Online forum:

A total of 6,654 members (a rise of approximately 7.10% from last year, not including the amounts of leavers due to being deceased or through choice)

There were 1028 requests to join the forum reviewed resulting in 441 new members. The high number of declined requests highlights the amount of fake AI and spam bot requests and the extra vigilance required when reviewing.

Patient Information Booklets

This financial year, we posted our patient information booklets to 1,065 households and emailed booklets to 36 households. across the UK.

We met with the Manchester Hindi community at the Indian Senior Citizens Centre, collaborating with local surgeon Mr Jain to host an awareness day and plan translation of key FBC resources into Hindi.

Our Awareness Raising Activities

Wee walks

Walking for bladder cancer is a global concept. People affected by the disease, whether they are patients, carers, family or friends, medical professionals or researchers, all walk in solidarity across the world, to raise awareness and much needed funds to help fight this disease.

This year, Wee Walks were held in Chinnor, Edinburgh, Fife and Bournemouth.

Other awareness raising activities

The Dundee United Football Club men's first team wore special orange t-shirts to warm up for their match against St Mirren on Saturday, 10th May to help raise awareness of bladder cancer and its common symptoms. Organised by Fight Bladder Cancer volunteer, Dorothy Markham, this initiative was the second time that The Tangerines have supported the charity by donning t-shirts emblazoned with common symptoms of bladder cancer, such as blood in urine.

The charity has also worked with Rhoda Grant MSP who supported the lighting of the Ness Bridge in orange for a weekend, hosted awareness-raising events at a local shopping centre, and held their 5th annual 'Wee Walk' on May 31st in Falkland.

We attended the Daiichi Sankyo European Patient Advocacy Forum 2024 representing Fight Bladder Cancer and the World Bladder Cancer Patient Coalition.

Bladder Cancer Awareness Month, May 2024

This May we had orders for our materials flying out of the office all month and we saw many of our supporters helping to raise essential awareness for bladder cancer. Not only did we see record numbers of sign ups for our awareness packs, we had so many people fundraising for us and most importantly, helped to spread our BCAM messages out to so many people. From bungee jumpers to visiting Westminster, to cake sales and ultra-marathon runners, to hospitals going orange and our 19 fundraising challengers, we raised over £27,000.

We also worked in collaboration with the World Bladder Cancer Patients Coalition (WBCPC), sharing their 'Spot the Drop' awareness campaign using the 'Unsure Icon', which saw the following impressions:

- Reached over 11 million people across our social media platforms
- People have played the #SpotTheDrop game over 53,000 times
- The Unsure Icon video now reached over 145,000 views
- The #BladderCancerMonth24 hashtag was mentioned over 4000 times

Cancer 52 Big Cancer Conversation

We joined in the Cancer 52 "Big Cancer Conversation" which took place at Canary Wharf

Key presenter in Merck Bladder Cancer Awareness Roadshow (Gillingham and Cork sites).

Royal College of GPs Conference

In April 2024, Fight Bladder Cancer attended the Royal College of GPs Conference, raising awareness of bladder cancer to primary care professionals from across the UK.

BAUN Conference

We attended the British Association of Urological Nurses (BAUN) Conference in Liverpool where we were able to catch up with some of the amazing Urology nurses who use our Patient Information Booklets, leaflets and posters to advise and inform their patients.

Poole Hospital Stoma Department

Deb Major, one of our previous trustees and a regular volunteer, took a table at the Poole Hospital Stoma Department open day., where she chatted with bc patients and carers, and handed out some of our information leaflets.

Our Policy & Advocacy Activities

Fight Bladder Cancer Event at the Houses of Parliament

We extend our heartfelt gratitude to everyone who supported the Fight Bladder Cancer event at the Houses of Parliament, which took place on May 21st during Bladder Cancer Awareness Month. The event was sponsored by MP Andy McDonald and was well attended by 18 MPs who stopped by to show their support for bladder cancer and learn more about the ways that they can support care improvements across the UK. This significant event aimed to elevate the conversation about bladder cancer, ensuring it becomes a priority on the parliamentary agenda. Our goal was to secure commitments from MPs to help achieve our policy objectives.

Policy asks of newly elected Labour government

Following the election of a new government in May 2024, Fight Bladder Cancer raised some of the issues facing bladder cancer and policy changes we would like to see from the new government:

- Enquire about a national bladder cancer audit to reduce regional variations in care.
- Push for updated bladder cancer guidelines, which have not been revised since 2015.
- Advocate for self-referral pathways to expedite diagnosis.
- Standardise fast-track referral criteria across the UK.
- Optimise the NHS 111 referral pathway for early detection of bladder cancer.
- Ensure access to genomic testing for high-risk patients.
- Reintroduce and support the Tobacco & Vapes Bill in Parliament to ensure its passage

NHS England 10-year Plan workshop

We hosted a workshop to gather patient feedback on the NHS England 10-Year Health Plan, with a strong focus on the needs of bladder cancer patients. This was a crucial opportunity to ensure that our voices—those of patients, advocates, and professionals—are heard in shaping the future of healthcare.

The discussion touched on three major NHS proposals, the role of technology in healthcare, the shortage of nurses, and the urgent need for a national bladder cancer audit.

Fight Bladder Cancer at GMB Congress 2024

The GMB Congress 2024 was a significant event for Fight Bladder Cancer, where we had a dedicated booth to raise awareness and provide support for those affected by bladder cancer due to occupational exposure to cancer-causing chemicals.

We joined in the NICE Medical Technologies Advisory Committee Meeting – Early Value assessment. Robotic Assisted Surgery for soft tissue.

Melanie Costin represented Fight Bladder Cancer on the NHS England Timed Urology Diagnostic Pathway [NHS England » Implementing timed urology cancer diagnostic pathway – bladder, penile, renal and testicular](#)

HTA Appraisals for new therapies for bladder cancer

We contributed to the National Institute for Clinical Excellence (NICE) appraisals for Erdafitinib, and Enfortumab vedotin + Pembrolizumab, where we prepared and delivered patient evidence and spoke at committee meetings.

We also participated in the Scottish Medicines Consortium (SMC) Patient and Clinician Engagement (PACE) meeting for Erdafitinib.

These had successful outcomes, resulting in approval of the first personalised and targeted treatments for advanced bladder cancer.

Dec 2024 Scottish Parliamentary Event

We were visited by and had conversations with 24 MSPs at our exhibition in the Scottish Parliament exhibition, our sponsoring MSP, Stuart MacMillan offered to help us get a debate on bladder cancer in the Scottish Parliament in 2025.

European Association of Urology (EAU)

EAU Patient Office (Headquarters in Brussels) - Melanie Costin was a guest speaker for newly elected MEPs highlighting the patient experience, key challenges in bladder cancer care, and policy priorities.

We attended the EAU Congress in Paris. Trustee Alison Birtle spoke about "Common Problems and Controversies in Bladder Cancer"

Our Research Activities

Melanie Costin, our Director of Patient Engagement and Support is in high demand as a patient advocate and key opinion leader for bladder cancer in the UK and globally. Some of her activity for financial year 2024-2025 is listed below:

- Attended a meeting with Merck R&D global leaders to discuss their research and ask her opinions as a patient.
- Attended the UK Bladder Cancer Research Day TOUR at the Edgbaston Hotel which was a fully interactive bladder cancer clinical research meeting led by an international expert panel of clinicians and scientists in the U.K. Came in the top three for her abstract, and was a 1st prize poster presentation winner.
- Member of the Anktiva Advisory Board and Co-PI for Patient Preference Study

- Was a patient expert consultant for the Ipsen Phase 1/2 IPN01203 clinical trial study design.
- Worked on Merck Europe Bladder Cancer Companion App, co-designing, and then testing for four months.
- Attended the ESMO conference in Barcelona covering a huge range of bladder cancer and urinary topics. She chaired EONS17 session on Optimal Biomarker Testing in GU Cancer; participated in the MSD advocacy forum and AstraZeneca multi-stakeholder roundtable to improve cancer outcomes, and spoke at KEYNOTE pre-conference symposium along with Dr Ignacio Duran for MSD
- Appointed Global Patient Advocate for Johnson & Johnson US (2025).
- Attended the EAU25 Congress in Madrid covering such topics as “Building Trust in the Patient-Doctor relationship” and “Case-based debates on complex urothelial cancer cases.” Came in the top five for her poster abstract, won 2nd prize for her poster, gave two Patient Plaza talks (Building Trust in the Patient-Doctor Relationship and The Impact of Cancer on Mental Health).

Financial Review

Where our money comes from:

In 2024–2024, the charity raised £603,483 from diverse income sources, an increase from the £327,027 raised in 2023– 2024. This was in part due to a very generous unrestricted grant of £250,000 from the Dianne & Graham Roberts Charitable Settlement.

We couldn't do our work without our amazing supporters, volunteers and campaigners. Our life-changing work would not be possible without such generous people. We appreciate every single gift we receive and work hard to ensure that no penny is wasted in our fight against bladder cancer.

Our money comes from lots of different places. We aren't reliant on one funding source, which is good, especially in today's financial environment, as we aim to increase both

funding and develop different sources in the future, to allow us to extend the work we do for Bladder Cancer patients and their families.

Fundraising Activities

We are incredibly grateful to all our fantastic fundraisers and grant makers who raised vital funds for us. Of special note is the generosity of the Dianne & Graham Roberts Settlement Trust which gave us £250,000 in memory of Graham Roberts.

Our largest fundraising page of the year came from Peter, a bladder cancer patient who spent a week walking the Pilgrim's Way route and raised an incredible £9,400 for us. Joined along parts of the route by loved ones, Peter wanted "to celebrate and to raise funds for FBC: Support - which has been a very valuable source of information, friendship and support".

2024/5 also saw our charity go global, with runners in iconic marathons all over the world! Big well done to all those who ran the 26.2 miles in Boston, Tokyo, New York, Chicago and finally, London! A special shoutout goes to Helen Tabor, a fundraising superstar who has been raising awareness and funds for bladder cancer since 2019 after her father passed away from bladder cancer 2 years before. March 2025 marked her final of the Six Major Marathons completed, wearing her 'good luck charm' orange vest and running in memory of her father-in-law too, who also passed away from bladder cancer in April 2024.

In memory funds and tribute pages also make a huge and heartfelt difference to the work we do and lasting relationships we have with patients and families we support. With over £15,000 raised in 2024/25 just from MuchLoved and funeral collections, FBC is chosen and trusted by families all across the UK to be their charity of choice when going through such hardships and loss.

Fundraising and taking on challenges in memory of a loved one is something we saw plenty of, with notable examples including Zack Moules who ran 21 ½ marathons in memory of his dad John in a year, a corporate challenge where the CountryStyleFoods company in Leeds walked the Yorkshire 3 Peaks to honour their colleague (raising an incredible £5,300 in her name) and Hugo, who ran the Rob Burrows Marathon and raised an inspiring £7,000 for his mum who passed away from bladder cancer when he was a young boy.

We work closely with the giving platform Enthuse to give our supporters a customisable, user-friendly place to donate or create a page that inspires their loved ones to support their fundraising for FBC. May 2024 saw one of our highest Enthuse monthly payouts ever, with a huge £16,800 total raised from our Bladder Cancer Awareness Month (BCAM) fundraising activities. Bungee jumps, duck races, hospital awareness takeovers, 10k's (and more!) all led up to the amazing achievement of a grand BCAM total of £27,163.

We would like to extend our thanks to the following companies who gave us grants this financial year:

Astellas Pharma Ltd

Astra Zeneca

Gilead Sciences Ltd

Janssen - Cilag Ltd

Merck Serono Ltd

Nucleix

Prokarium Ltd

We would like to thank the following trusts and foundations who donated to Fight Bladder Cancer this financial year:

Dianne & Graham Roberts Charitable Settlement

Lord Faringdon Charitable Trust

Sidney & Phyllis Goldberg Memorial Trust

Sir Jules Thorne Charitable Trust

William Brake Foundation

William and Mabel Morris Charitable Trust.

How we spend our money

The total expenditure 2024-2025 was £420,338; in 2022-2023 it was £334,312. We understand that when anyone makes a charitable donation, they want to know exactly

where that money is going, and we pledge to be clear and transparent when it comes to spending every contribution.

We assure you that every pound is important, and we are committed to judiciously considering where we spend our income and what we commit our money to. We make every penny count.

Reserves Policy

The Trustees have forecast the level of free reserves (those funds not tied up in tangible fixed assets or categorised as restricted funds) that the Charity will require to sustain its operations in a period when it could be anticipated that there may be some reduced income performance. Such reduction in income may lead to the curtailment or cancellation (temporarily or otherwise, depending on the specific nature of the income reduction) of projects detailed in the strategic plan (whether in progress or not yet commenced). The overriding concern of the Trustees at such a time will be the maintenance of the services that provide the most benefit to people affected by bladder cancer, namely disease awareness and personal support.

The Trustees consider that the most appropriate level of free reserves to be held by the Charity should be sufficient to cover six months of budgeted forecast expenditure.

Whilst the current level of income generated may prove sufficient to meet identified requirements, it is the Trustees' view that there should be sufficient free reserves available to provide financial flexibility, having regard to known and anticipated future expenditure and to provide contingency funding to meet any shortfall in income generation and any unplanned emergency expenditure which may be required.

Therefore, the Trustees' policy is to closely monitor the Charity's financial and operational activities and maintain free reserves within the parameters identified above.

The reserves policy states that the Charity should have unrestricted funds equivalent to six months of budgeted forecast expenditure – £239,249. The unrestricted funds for general use as of 31 March 2025 were £493,332 equivalent to 12.4 months of budgeted forecast expenditure.

Exemptions from disclosure

The Charity did not undertake any grant- making activity in the year ended 31 March 2025. The Charity has disclosed all relevant key personnel details.

Funds held as custodian trustees on behalf of others

The Charity did not act as a custodian Trustee for the assets of any other charity in the year ended 31 March 2025.

Income and Expenditure

The results for the year are set out in the financial statements below. The financial statements show a total income for the year ended 31 March 2025 of £603,483 (year ended 31 March 2024: £327,027).

The total expenditure was £ 420,338 (year ended 31 March 2025: £334,309).

Net assets

For the year ended 31 March 2025, the Charity had tangible assets of £5,002 (year ended 31 March 2024: £3,959), stocks of £5,971 (year ended 31 March 2024: £3,915), debtors of £10,400 (year ended 31 March 2024: £22,933), cash of £327,985 (year ended 31 March 2024: £143,964).

The Charity had amounts falling due within one year of £13,257 (year ended 31 March 2024: £21,815), leaving it with net assets of £336,101 (year ended 31 March 2024: £152,956).

For the year ended 31 March 2025, the Charity had restricted funds of £66,975 (year ended 31 March 2024: £69,303), and funds remaining for general use were £269,126 (year ended 31 March 2024: £83,653). On 31 March 2025, the bank balance was £336,101.

Going concern

When approving the financial statements, the Trustees acknowledge that the financial statements for the year ended 31 March 2025 reflect a surplus and are consistent with the Trustees' Reserves Policy. Despite that, the Trustees have implemented measures to improve the financial stability of the charity longer term. This positive trend supports the Trustees' confidence in the charity's ability to meet its financial commitments and continue its operations in the foreseeable future. Accordingly, the Trustees believe that the Going Concern basis is the appropriate basis for preparing the accounts.

Future Plans

With the resignation of our CEO, Lydia Makaroff, we will be seeking the recruitment of a new CEO through the use of a charity recruitment firm. This is to ensure that we recruit a high calibre candidate with experience of running and growing a charity.

Following on from that we will be looking to develop our strategy for 2026 - 2031 with a focus on growth not just in terms of financial activities, but the growth of our patient, carer and family services, to reach a wider and more diverse audience.

In 2025-2026, we will look to implement a nationwide public bladder cancer awareness campaign of the signs and symptoms of the disease and implement awareness campaigns and educational programmes for primary care professionals.

We will scale up and strategise our policy and advocacy activities across all four nations, advocating for patients amongst policymakers and governments.

We will invest in fundraising activities and develop a strategic approach to grow income from more diverse income streams than currently.

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

The financial statements were approved, and authorised for issue, by the Trustees on 17th December 2025 and signed on their behalf by: -

A handwritten signature in black ink, appearing to read "A Dearden".

Andrew Dearden, Chair of Trustees

INDEPENDENT EXAMINER'S REPORT TO THE BOARD OF TRUSTEES**For the year ended 31 March 2025**

I report on the accounts of the charity for the year ended 31 March 2025.

Respective responsibilities of the Trustees and examiner

As the trustees of the charity, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities and Trustee Investment (Scotland) Act 2005 ('the 2005 Act'), the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 ('the 2011 Act'). You are satisfied that the accounts of the Charity are not required by charity law to be audited and have chosen instead to have an independent examination.

Having satisfied myself that the accounts of the Charity are not required to be audited and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 44 (1) (c) of the 2005 Act and section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the requirements of Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Basis of independent examiner's statement

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the Charity, and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts and seeking explanations from you as Trustee concerning any such matters.

The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a "true and fair view", and this report is limited to those matters set out in the statement below.

Independent examiner's statement

Since the Company is required by company law to prepare its accounts on an accruals basis and is registered as a charity in Scotland your examiner must be a member of a body listed in Regulation 11(2) of the Charities Accounts (Scotland) Regulations 2006 (as amended). I can confirm that I am qualified to undertake the examination because I am a registered member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. the accounts do not accord with such records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view which is not a matter considered as part of an independent examination or
4. the accounts have not been prepared in accordance with the Charities SORP (FRS102).

/Continued...

INDEPENDENT EXAMINER'S REPORT TO THE BOARD OF TRUSTEES

For the year ended 31 March 2025

/Continued...

I understand that the financial statements have been prepared to give a 'true and fair' view, and have departed from the Charities (Accounts and Reports) Regulations 2008, only to the extent required to provide a 'true and fair view'. This departure has involved following SORP 2015 FRS102, rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 (SORP 2005), which is referred to in the extant regulations, but has since been withdrawn.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

A handwritten signature in blue ink, appearing to read 'Ssempijja', with a horizontal line underneath.

Charles Ssempijja, FCA
NfP Accountants Ltd
Chartered Accountants
3rd Floor, 86-90 Paul Street
London
EC2A 4NE

Date: 18 December 2025.....

STATEMENT OF FINANCIAL ACTIVITIES

For the year ended 31 March 2025

	Notes	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Unrestricted Funds 2024 £	Restricted Funds 2024 £	Total Funds 2024 £
INCOME FROM							
Donations and legacies	2	447,308	108,529	555,837	186,606	108,167	294,773
Other trading activities	3	27,443	1,622	29,065	12,561	-	12,561
Other income		18,581	-	18,581	19,693	-	19,693
Investment income		-	-	-	-	-	-
TOTAL INCOME		493,332	110,151	603,483	218,860	108,167	327,027
EXPENDITURE ON:							
Awareness		106,919	32,250	139,169	78,340	27,531	105,871
Support		64,168	49,398	113,566	18,070	81,281	99,351
Policy Change		49,521	18,478	67,999	74,093	998	75,091
Research		43,905	12,353	56,258	20,806	4,110	24,916
		264,513	112,479	376,992	191,309	113,920	305,229
Raising funds	4	43,346	-	43,346	29,080	-	29,080
TOTAL EXPENDITURE		307,859	112,479	420,338	220,389	113,920	334,309
Net income/(expenditure) before transfers		185,473	(2,328)	183,145	(1,529)	(5,753)	(7,282)
Net income / (expenditure) for the year		185,473	(2,328)	183,145	(1,529)	(5,753)	(7,282)
Transfer between funds	14	-	-	-	(918)	918	-
NET MOVEMENT IN FUNDS		185,473	(2,328)	183,145	(2,447)	(4,835)	(7,282)
RECONCILIATION OF FUNDS							
TOTAL FUNDS AT BROUGHT FORWARD		83,653	69,303	152,956	86,100	74,138	160,238
TOTAL FUNDS CARRIED FORWARD		£ 269,126	£ 66,975	£ 336,101	£ 83,653	£ 69,303	£ 152,956

The annexed notes form part of these financial statements

FIGHT BLADDER CANCER

(Registered charity number 1157763)

BALANCE SHEET

As at 31 March 2025

	Notes	2025	2024
		£	£
FIXED ASSETS			
Tangible assets	11	5,002	3,959
CURRENT ASSETS			
Stocks		5,971	3,915
Debtors	12	10,400	22,933
Cash at bank and in hand		327,985	143,964
		<u>344,356</u>	<u>170,812</u>
CREDITORS: amounts falling due within one year	13	(13,257)	(21,815)
NET CURRENT ASSETS		<u>331,099</u>	<u>148,997</u>
NET ASSETS		<u>£ 336,101</u>	<u>£ 152,956</u>
FUNDS			
Restricted funds	14	66,975	69,303
General fund	14	269,126	83,653
		<u>£ 336,101</u>	<u>£ 152,956</u>

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

The financial statements were approved, and authorised for issue, by the Trustees on 17th December 2025 and signed on their behalf by: -



Andrew Dearden, Chair

FIGHT BLADDER CANCER

STATEMENT OF CASH FLOWS For the year ended 31 March 2025

	2025		2024	
	£	£	£	£
Cash flows from operating activities				
Net income for the period		183,145		(7,282)
Add back depreciation		3,495		2,406
Change in stock		(2,056)		(1,114)
Net cash provided by / (used in) operating activities				
(Increase)/decrease in debtors	12,533		34,789	
Increase/(decrease) in creditors	(8,557)		3,658	
		3,976		38,447
Cash flows from investing activities				
Purchase of fixed assets		(4,780)		(2,349)
Sale of fixed assets		241		365
Cash flows from financing activities		-		-
Change in cash and cash equivalents in the year		184,021		30,473
Cash and cash equivalents at the beginning of the year		143,964		113,491
Cash and cash equivalents at the year end		327,985		143,964

NOTES TO THE FINANCIAL STATEMENTS**For the year ended 31 March 2025**

1. ACCOUNTING POLICIES***Basis of preparation of financial statements***

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (Charities SORP FRS 102), the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following SORP 2015 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 (SORP 2005) which has since been withdrawn.

Public benefit entity

The charity meets the definition of a public benefit entity under FRS 102.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

Income

Income is recognised when the charity has entitlement to the funds: this is when any performance conditions attached to the income have been met, it is probable that the income will be received, and that the amount can be measured reliably.

Income is only deferred when: the donor specifies that the grant or donation must only be used in future accounting periods; or for performance related grants, where these are received in advance of the performances or specific event to which they relate.

Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Fund accounting

Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

Unrestricted funds are donations and other incoming resources received or generated for the charitable purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

NOTES TO THE FINANCIAL STATEMENTS**For the year ended 31 March 2025**

Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is considered all to relate to Charitable activities and includes the costs of delivering services undertaken to further the purposes of the charity and their associated support costs.

Charitable activities costs

Direct costs of charitable activities are those costs incurred by the charity and are directly attributable to the delivery of its activities. The total costs of each charitable activity also includes allocated staff and support costs.

Allocation of staff costs

Staff costs are allocated to charitable activities on the basis of staff effort, for example by reference to staff time, for each activity.

Allocation of support and governance costs

Support and governance costs are allocated between charitable in proportion to staff costs.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Judgements and key sources of estimation uncertainty

No judgements have been made in the process of applying the above accounting policies and there are no key sources of estimation uncertainty.

Foreign currencies

The reporting currency is GBP. The Foundation operates a no loss no gains policy with regard to currency fluctuations between GBP and Kenyan Shillings. Currency fluctuation is contained within

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2025

Intangible assets

Intangible assets are stated in the Balance Sheet at cost less accumulated amortisation and impairment. They are amortised on a straight line basis over their estimated useful lives as follows:

Website - 20% straight line

Tangible fixed assets

Individual fixed assets cost £300 or more are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses, calculated as follows:

Office equipment - 25% straight line

2. DONATIONS AND LEGACIES

	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Total Funds 2024 £
Donations received	25,194	-	25,194	24,511
Donations in Memorium	33,595	-	33,595	20,875
Grants - Pharmaceutical donors	2,000	104,479	106,479	100,307
Grants Received - Other	283,000	3,650	286,650	39,750
Fundraising activities	103,251	400	103,651	106,932
Other fundraising income	268	-	268	2,398
	£ 447,308	£ 108,529	£ 555,837	£ 294,773
2024				
<i>Donations received</i>	24,511	-	24,511	
<i>Donations in Memorium</i>	20,875	-	20,875	
<i>Grants - Pharmaceutical donors</i>	11,250	89,057	100,307	
<i>Grants Received - Other</i>	21,000	18,750	39,750	
<i>Fundraising activities</i>	106,572	360	106,932	
<i>Other fundraising income</i>	2,398	-	2,398	
	£ 186,606	£ 108,167	£ 294,773	

Grants received - other: this includes government grants through the Kickstart scheme amounting to £0,000 (2024 - £0,000).

FIGHT BLADDER CANCER

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2025

3. INCOME FROM OTHER TRADING ACTIVITIES

	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Total Funds 2024 £
Sales	1,949	172	2,121	2,363
Fees received	25,219	1,450	26,669	9,844
Sundry income	275	-	275	354
	£ 27,443	£ 1,622	£ 29,065	£ 12,561

4. ANALYSIS OF EXPENDITURE

Current year	Staff / consultant costs £	Direct costs £	Support costs £	Total 2025 £	Total 2024 £
Charitable activities					
- Awareness	59,468	37,013	42,688	139,169	105,871
- Support	37,126	49,789	26,651	113,566	99,351
- Policy Change	35,987	6,179	25,833	67,999	75,091
- Research	31,263	2,553	22,442	56,258	24,916
	163,844	95,534	117,614	376,992	305,229
Fundraising costs	37,783	5,563	-	43,346	29,080
Governance & support costs	43,821	73,793	(117,614)	-	-
	£ 245,448	£ 174,890	£ Nil	£ 420,338	£ 334,309

	Staff / consultant costs £	Direct costs £	Support costs £	Total 2024 £
Charitable activities				
- Awareness	53,418	24,634	27,819	105,871
- Support	45,680	29,882	23,789	99,351
- Policy Change	43,273	9,283	22,535	75,091
- Research	15,536	1,289	8,091	24,916
	157,907	65,088	82,234	305,229
Fundraising costs	19,980	9,100	-	29,080
Governance & support costs	27,440	54,794	(82,234)	-
	£ 205,327	£ 128,982	£ Nil	£ 334,309

Of total expenditure of £420,338, £112,479 (2024 - £113,920) was out of restricted income funds, and £307,859 (2024 - £220,389) was unrestricted.

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2025

5. TRUSTEES' REMUNERATION AND EXPENSES

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year (2024 - none).

3 trustees were reimbursed for out of pocket expenses amounting to £1,345 during the year (2024 - none).

6. OTHER RELATED PARTY TRANSACTIONS

There were no other disclosable related party transactions (2024 - the same).

7. STAFF COSTS AND NUMBERS

	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Total Funds 2024 £
Salary costs				
Wages and salaries	157,706	44,069	201,775	171,868
Social security costs	10,763	2,929	13,692	11,740
Employer's pension	8,726	3,270	11,996	5,489
	<u>£ 177,195</u>	<u>£ 50,268</u>	<u>£ 227,463</u>	<u>£ 189,097</u>

The monthly average number of persons (including senior management team) employed by the charity during the year was 6 (2024 - 6).

One employee received emoluments of more than £60,000 (£60,000 - £70,000), including benefits, during the year (2024 - one employee (£70,000 - £80,000)).

Total remuneration for key management personnel amounted to £149,481 during the year (2024 - £110,373).

8. PENSIONS

The charity operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the charity to the scheme and amounted to £11,996 (2024 - £5,489).

FIGHT BLADDER CANCER

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2025

9. SUPPORT AND GOVERNANCE COSTS

	2025	2024
	£	£
Governance costs:		
Independent Examiner's fee	1,800	1,800
Other governance costs	3,840	725
	5,640	2,525
Support staff costs: wages and salaries	43,821	27,440
Other staff costs	21,054	14,643
Premises costs	25,705	23,185
IT and equipment	5,340	5,802
Postage, printing, and communications	3,237	3,198
Graphic Design	1,086	1,020
Professional fees	8,027	536
Depreciation and amortisation costs	3,496	2,406
Sundry	208	1,479
	£ 117,614	£ 82,234

Support costs all relate to the charitable activities on the basis of staff time.

10. INTANGIBLE FIXED ASSETS

	£
Website	
Cost	
At 1 April 2024 and at 31 March 2025	21,631
Amortisation	
At 1 April 2024 and at 31 March 2025	21,631
Net book value	
At 31 March 2025	£ Nil
At 31 March 2024	£ Nil

FIGHT BLADDER CANCER

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2025

11. TANGIBLE FIXED ASSETS

	Office equipment £
Cost	
At 1 April 2024	18,496
Additions	4,780
Disposals	(967)
At 31 March 2025	<u>22,309</u>
Depreciation	
At 1 April 2024	14,537
Charge for the year	3,495
On disposals	(725)
At 31 March 2025	<u>17,307</u>
Net book value	
At 31 March 2024	£ 3,959
At 31 March 2025	<u>£ 5,002</u>

12. DEBTORS

	2025 £	2024 £
Due within one year		
Trade debtors	3,142	1,109
Prepayments	7,258	21,821
VAT debtor	-	3
	<u>£ 10,400</u>	<u>£ 22,933</u>

FIGHT BLADDER CANCER

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2025

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025 £	2024 £
Trade creditors	6,702	16,023
Net wages	1	-
Social security and other taxes	3,401	3,682
Other creditors	1,053	10
Accrued expenses	2,100	2,100
	£ 13,257	£ 21,815

14. STATEMENT OF FUNDS

	Brought Forward £	Incoming Resources £	Resources Expended £	Transfers and investment gains/(losses) £	Carried Forward £
RESTRICTED FUNDS					
Awareness	7,966	50,556	(32,250)	-	26,272
Policy change	-	31,450	(18,478)	-	12,972
Research	11,802	15,650	(12,353)	-	15,099
Support	49,535	12,495	(49,398)	-	12,632
	£ 69,303	£ 110,151	£ (112,479)	£ Nil	£ 66,975
SUMMARY OF FUNDS					
General Funds	83,653	493,332	(307,859)	-	269,126
Restricted Funds	69,303	110,151	(112,479)	-	66,975
	£ 152,956	£ 603,483	£ (420,338)	£ Nil	£ 336,101

FIGHT BLADDER CANCER

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2025

STATEMENT OF FUNDS CONTINUED - 2024

	<i>Brought Forward</i>	<i>Incoming Resources</i>	<i>Resources Expended</i>	<i>Transfers and investment gains/(losses)</i>	<i>Carried Forward</i>
	£	£	£	£	£
RESTRICTED FUNDS					
<i>Patient Booklets</i>	54,477	61,750	(77,773)	-	38,454
<i>Contact Cards</i>	13,589	-	(3,508)	-	10,081
<i>Awareness</i>	-	29,505	(21,539)	-	7,966
<i>Website</i>	6,072	-	(6,990)	918	-
<i>Support</i>	-	1,000	-	-	1,000
<i>Research</i>	-	15,912	(4,110)	-	11,802
	<u>£ 74,138</u>	<u>£ 108,167</u>	<u>£ (113,920)</u>	<u>£ 918</u>	<u>£ 69,303</u>

SUMMARY OF FUNDS - 2024

<i>General Funds</i>	86,100	218,860	(220,389)	(918)	83,653
<i>Restricted Funds</i>	74,138	108,167	(113,920)	918	69,303
	<u>£ 160,238</u>	<u>£ 327,027</u>	<u>£ (334,309)</u>	<u>£ Nil</u>	<u>£ 152,956</u>

Description of funds

Patient booklets

A new initiative to develop, produce, launch, and distribute a suite of ten patient information booklets designed to support patients on every step of their bladder cancer pathway.

Health Professional Contact Cards

Personalised business cards for nurses and other health professionals to give to patients, with the charity's support services and their own contact details.

Exemplar

The project seeks to define what exceptional services for people affected by bladder cancer would look like.

Patient Advocates

The recruitment, training, and support of people affected by bladder cancer to share their insights and lead the work of the charity.

Website

Refreshing fightbladdercancer.co.uk to ensure that it contains current and accessible information about the diagnosis, treatment, and care of bladder cancer.

FIGHT BLADDER CANCER

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2025

15. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted Funds		Restricted Funds	Total Funds
	Designated Funds	General Funds		
	£	£	£	£
Tangible fixed assets	-	5,002	-	5,002
Net current assets	-	264,124	66,975	331,099
	<u>£ Nil</u>	<u>£ 269,126</u>	<u>£ 66,975</u>	<u>£ 336,101</u>

16. OPERATING LEASE COMMITMENTS

The charity had no operating lease commitments (2024 - the same).

17. OTHER COMPANY INFORMATION

Fight Bladder Cancer is a registered non-company charity, charity commission registration number 1157763. The registered office is 51 High Street Chinnor Oxfordshire OX39 4DJ. The accounts are presented in GBP to the nearest £1.

INDEPENDENT EXAMINER'S REPORT TO THE BOARD OF TRUSTEES**For the year ended 31 March 2025**

I report on the accounts of the charity for the year ended 31 March 2025 set out on pages 12 to 18.

Respective responsibilities of the Trustee and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- follow the procedures laid down in the general Directions given by the Charity Commissioners under section 145(5)(b) of the 2011 Act; and
- state whether particular matters have come to my attention.

Basis of the independent examiner's statement

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a "true and fair view" and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

(1) which gives me reasonable cause to believe that in any material respect the requirements

- to keep accounting records in accordance with section 130 of the 2011 Act; and
- to prepare accounts which accord with the accounting records and comply with the accounting requirements of the 2011 Act

have not been met; or

(2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

Simon Erskine, FCA FCIE DChA

61 Mortimer Road

London

NW10 5QR

Date: